PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY

Highlights of the congress

CHALLENGES AND OPPORTUNITIES IN THE MANAGEMENT OF AGGRESSIVE B CELL LYMPHOMAS

IMMUNOTHERAPY IN LYMPHOMAS / CHECKPOINT INHIBITORS

NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOWUP OF THE PHASE 2 CHECKMATE 205 TRIAL

IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN

Highlights of the congress

BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB AND VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)